It is not the same with or without GalChimia
GalChimia in J. Med. Chem. – A New Clinical Candidate for Pain ManagementDecember 1, 2020
Our latest article with Esteve Pharmaceuticals is now available in J. Med. Chem., with participation as well of researchers from UPF and UGR. Click here to read it!Read More
GalChimia in RSC Med. Chem. – Drug Discovery for the Treatment of Visceral LeishmaniasisAugust 20, 2020
Check out our new paper about the identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasisRead More
White Paper – Napropamide Impurities and MetabolitesJuly 22, 2020
We are excited to present the work carried out in collaboration with Hypha Discovery for the preparation of a wide range of napropamide derivatives with great interest to the agrochemical industry.Read More
Consortium: Alchemy and GalChimia
Within the framework of the 2018 INNOGLOBAL programme, the Centre for Industrial Technological Development (CDTI) has awarded funding for the project “New drug candidates for non-small cell lung cancer treatment: lead optimisation and development of CTP inhibitors“. Its objective is to develop new drugs for the treatment of non-small cell lung cancer (NSCLC).
The project has a budget of €234,418.00 and is funded by the CDTI under the Spanish National Programme for Business Leadership in R&D, within the framework of the Spanish National Plan for Scientific and Technical Research and Innovation 2017–2020, and supported by the Spanish Ministry of Economy, Industry and Competitiveness.
Within the framework of the RETOS 2017 partnership programme, the Spanish Ministry of Science, Innovation and Universities (MICINN) has awarded funding for the project “Discovery of agrochemicals to improve drought tolerance in crop plants“, led by GalChimia, S.A. Its main objective is the development of a new generation of compounds that can activate drought tolerance in crop plants. To this end, the project is supported by the Institute for Plant Molecular and Cellular Biology (IBMCP), the Rocasolano Institute of Physical Chemistry (IQFR), and the BioFarma and Nanobiomol groups of the University of Santiago de Compostela.
The project has a budget of €572,999.89, and is funded by the RETOS-COLABORACIÓN 2017 subprogramme, and co-funded with Structural Funds from the European Regional Development Fund (ERDF) and by the Spanish State Research Agency (AEI), with the objective of promoting technological development, innovation and quality research.
A collaborative effort to boost EU synthetic biology competitiveness
The ShikiFactory100 Horizon2020 project gathers 11 partners from 7 countries: SilicoLife (Portugal), Technical University of Denmark, European Molecular Biology Laboratory (Germany), École Polytechnique Fédérale de Lausanne (Switzerland), NOVA University of Lisbon (Portugal), University of Manchester (UK), University of Minho (Portugal), c-LEcta (Germany), GalChimia (Spain), NNFCC (UK), and DSM (The Netherlands).
The project will provide economically feasible and sustainable biotechnological processes as alternatives to oil-based chemistry. The global chemical industry has initiated a crucial transition from petrochemical processes to bio-based chemical processes. The ShikiFactory100 project aims toward the production of a pool of more than 100 high-value compounds from the shikimate pathway, a hub in cell metabolism, through the development of an optimized chassis and the proposal and implementation of novel biosynthetic routes for the production of known and new molecules.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 814408.
Industrial Research to discover new immunotherapy drugs for the treatment of colon cancer
The main objective of the IO4COLON project is the discovery and preclinical development of new medicinal product candidates for the treatment of colon cancer by activating the immune system (IS), to be used in monotherapy, in combination, or with other therapeutic agents. The project is being led by the companies Oncostellae, GalChimia, and AMSLab, with the support of the University of Santiago de Compostela, LEITAT Technological Centre, and the companies Palo Biofarma, IDIFARMA, and Eurofins.
IO4COLON will study the efficacy of two new medicinal products, an ALK5 inhibitor and a GR antagonist, through various mechanisms, while also studying their synergistic effect in the treatment of colon cancer. IO4COLON also represents a considerable qualitative leap in comparison to previous projects, as the aim is to complete Preclinical Development, Pharmaceutical Development, the production of capsules for clinical trials, the preparation of the regulatory documentation, and the potential use of the results through the application for new invention patents.
This project is subsidised by the Galician Innovation Agency (GAIN), through the CONECTA-PEME Programme, and the European Regional Development Fund within thematic objective 1, “Strengthening research, technological development and innovation“, included within the framework of the FEDER Galicia 2014–2020 operational programme, and will also be supported by the Consellería de Economía, Emprego e Industria [Galician Ministry for the Economy, Employment and Industry]. Total project budget: 1,095,700.00 euros.